Lupus erythematosus
Drug research and approvals for lupus erythematosus: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 296 studies of lupus erythematosus are recruiting on ClinicalTrials.gov, Health Canada has authorized 51 drug trials for it since 2013, FDA has 0 approved and 3 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 296
- Trials authorized in Canada: 51
- FDA orphan approvals: 0
- EU medicines: 2
Recruiting Now
Newest start dates first, of 296 recruiting on ClinicalTrials.gov ↗- Deciphering the Genetic Architecture of Autoimmune DiseasesNCT06948110 · Not reported · National Human Genome Research Institute (NHGRI) · starts Nov 19, 2026
- Pain Phenotyping of Rheumatic Diseases - An Observational StudyNCT07829497 · Not reported · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · starts Nov 9, 2026
- Study of Afimetoran in Adults With Cutaneous Lupus ErythematosusNCT07881120 · Phase 2 / Phase 3 · Beeline Medicines Corporation · starts Nov 3, 2026
- To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus…NCT07629583 · Phase 1 · Genentech, Inc. · starts Nov 2, 2026
- Autologous Stem Cell Transplant (ASCT) for Autoimmune DiseasesNCT05029336 · Phase 2 · Stephan Grupp MD PhD · starts Nov 1, 2026
- A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease…NCT07840287 · Phase 3 · EMD Serono Research & Development Institute, Inc. · starts Oct 22, 2026
- Lupus Nephritis Care PathwayNCT07783152 · Not applicable · Duke University · starts Oct 14, 2026
- FT839 in Autoimmune DiseasesNCT07800871 · Phase 1 / Phase 2 · Fate Therapeutics · starts Oct 1, 2026
- Pediatric Longitudinal Glomerular Disease: a PNRC Multi-Institutional Cohort StudyNCT07931170 · Not reported · Pediatric Nephrology Research Consortium · starts Oct 1, 2026
- A Study of ATG-201 in Adult Participants With Autoimmune DiseasesNCT07732309 · Phase 1 · Antengene Biologics Limited · starts Sep 26, 2026
Trials Authorized in Canada
The 10 newest of 51; search them all in Canada trials| Jul 30, 2026 | A phase 3, single-arm, open-label, long-term extension study to evaluate the safety and efficacy of enpatoran in participants with active cutaneous…ENPATORAN (E5049, M5049) | Merck KGaA | Pending |
| Mar 20, 2026 | A phase 3, randomized, double-blind, placebo-controlled parallel study to evaluate the efficacy and safety of enpatoran in participants with active cutaneous…ENPATORAN (M5049) | Merck KGaA | Pending |
| Mar 20, 2026 | A phase 3, randomized, double-blind, placebo-controlled parallel study to evaluate the efficacy and safety of enpatoran in participants with active cutaneous…ENPATORAN (M5049) | Merck KGaA | Pending |
| Jan 20, 2026 | Multinational, interventional, 52-week, open-label, single-arm study to evaluate the treatment outcomes of anifrolumab 120 mg subcutaneous once weekly in…ANIFROLUMAB (MEDI-546) | AstraZeneca Pharmaceuticals LP | Ongoing |
| Dec 23, 2025 | Phase 1b/2 study of azd0120, a chimeric antigen receptor t-cell (car t) therapy targeting cd19 and b-cell maturation antigen (bcma) in subjects with refractory…AZD0120 (GC012F) | AstraZeneca Pharmaceuticals LP | Pending |
| Aug 1, 2025 | A phase 2, multicenter, open-label study of cc-97540 (bms-986353), cd19-targeted nex-t car t cells, in participants with active sle (including lupus nephritis)…BMS-986353 (CC-97540) | Bristol-Myers Squibb | Ongoing |
| Jun 25, 2025 | A phase 2b, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of imvt-1402 in participants with active…IMVT-1402 | IMMUNOVANT SCIENCES GMBH | Closed |
| Apr 3, 2025 | Open-label, phase 1 study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of azd5492 folllowing single-ascending dose and step-up…AZD5492 | AstraZeneca Pharmaceuticals LP | Ongoing |
| Dec 17, 2024 | A phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus…YTB323 (RAPCABTAGENE AUTOLEUCEL) / FLUDARABINE PHOSPHATE / CYCLOPHOSPHAMIDE | Novartis Pharmaceuticals Corporation | Pending |
| Nov 14, 2024 | A phase I study to evaluate the safety and preliminary efficacy of ata3219, allogeneic anti cd19 chimeric antigen receptor t cell (car t) therapy, in subjects…ATA3219 / FLUDARABINE PHOSPHATE / CYCLOPHOSPHAMIDE / METHYLPREDNISOLONE SODIUM… | Atara Biotherapeutics | Pending |
FDA Orphan Designations
Approved first, then open designations, newest first| Feb 9, 1999 | Humanized MAb (IDEC-131) to CD40LTreatment of systemic lupus erythematosus. | Biogen IdecInc. | Designated |
| Feb 18, 1998 | Recombinant humanized monoclonal antibody 5c8Treatment of systemic lupus erythematosus. | Biogen, Inc. | Designated |
| Jul 13, 1994 | DehydroepiandrosteroneTreatment of systemic lupus erythematosus (SLE) and the reduction in the use of steroids in steroid-dependent SLE patients. | GlaxoSmithKline | Designated |
Medicines Authorised in the EU
Newest first| Feb 14, 2022 | Saphneloanifrolumab | AstraZeneca AB | EMA ↗ |
| Jul 13, 2011 | Benlystabelimumab | GlaxoSmithKline (Ireland) Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA